Transformative Dementia and Alzheimer’s treatment company Kurve Therapeutics launches $50m equity crowdfunding raise

Next-generation Medtech innovator Kurve Therapeutics begins an equity crowdfunding journey with its $50 million Regulation A+ raise.

Next-generation Medtech innovator Kurve Therapeutics begins an equity crowdfunding journey with its $50 million Regulation A+ raise.

September 14, 2022

Next-generation Medtech innovator Kurve Therapeutics begins an equity crowdfunding journey with its $50 million Regulation A+ raise.

Private investors can now invest in a company aiming to disrupt and transform a $1.3 trillion dementia market alone while benefiting millions living with neurodegenerative diseases.

Diseases like Dementia and Alzheimer’s afflict millions of people across the globe, while over 1 billion people worldwide – 1 in 6 – suffer from a neurological disease. Yet, Healthcare sectors lack effective, disease-modifying treatments.

Kurve Therapeutic’s patented intranasal drug delivery technology, Controlled Particle Dispersion^® (CPD), has been shown to bypass the blood-brain barrier, delivering 30x more medication directly to the brain than infusions.

Marc Giroux, Kurve Therapeutics CEO and founder said: “An IV infusion manages to deliver one-tenth of 1% through the blood-brain barrier. We have measured our success at 30 times more than that. This is not an insignificant achievement.

“Central nervous system disorders are a scourge because they are challenging to treat by their very nature. We have the potential to eliminate this problem, so an unmet need becomes a met need,”

Giroux now hopes to blast Kurve Therapeutics into a new growth period, teaming up with award-winning broker-dealer Rialto Markets‘ crowdfunding infrastructure and technology for its Regulation A+ offering:

“Following extensive work developing treatments and our CPD technology, we are ready to scale the company and grow our investor community.

“We plan to invest most of our proceeds into our final phase III clinical trials for intranasal insulin for mild cognitive impairment in Alzheimer’s. Kurve Therapeutics is ready for Phase III clinical trials in three separate disease states and is one Phase III study away from being eligible for FDA approval.”

Rialto Markets CEO and Co-founder Shari Noonan said: “Kurve Therapeutics’ intranasal drug delivery technology has the potential to transform the lives of millions suffering from neurodegenerative diseases.

“This is a very exciting and important sector that needs this essential innovation, so we are delighted that Kurve Therapeutics chose to work with us to grow and scale.”

Rialto Markets’ has a capital raising infrastructure for Reg CF and Reg A+ equity crowdfunding as well as Reg D institutional investment offering. Alongside this, Rialto Markets has a pioneering secondary market alternative trading system (ATS) which empowers the buying and selling of shares in private companies or other private securities, which can operate similarly in a regulated framework and environment as a stock exchange does such as the Nasdaq and NYSE for public company trading.

This secondary trading ATS allows private companies and shareholders to potentially create liquidity and trading within a $7 trillion-dollar private securities market set to grow to $30 trillion by 2030, potentially enabling greater access to vital funding and private securities within a fully regulated environment.

_______________________________________________________________
Rialto Markets is a FINRA member Broker-Dealer (Rialto Primary) and operates an alternative trading system (Rialto Secondary – Rialto MarketBoard™) for private securities including those issued as a Digital Asset Security. Rialto Primary supports companies issuing equity and debt securities through Reg A+, Reg CF, and Reg D exemptions. Rialto Markets is registered in all 50 states including those requiring a broker-dealer to issue Reg A+ securities

Kurve Therapeutics Led by a team of experienced entrepreneurs with successful track records in biotech, pharmaceuticals, and device technology, our mission is to pave the way in treating complex CNS disorders, including Alzheimer’s disease, cognitive aging, Lewy body dementia, Parkinson’s disease, and ALS. The Kurve technology is featured in 18 peer-reviewed publications in leading medical journals. Kurve technology has been used in five double-blind placebo-controlled Phase II studies and is ready for Phase III with Alzheimer’s patients.

Sign Up Now to Invest With Kurve!

*Founders, board, and management own 51% of common shares

16825 48th West Suite 434
Lynnwood, WA 98037

info@kurvetx.com
(425) 640-9249

Transfer Agent: KoreConX Inc. | Broker-Dealer: Rialto Markets LLC | Escrow Agent: Wilmington Trust NA The Refund Policy: There are no refunds or cancelations of commitments once the subscription agreement is signed and submitted. Please contact compliace@rialtomarkets.com with questions regarding a cancelation or refund.

Rialto Markets LLC is the Onboarding Agent for this offering and is not an affiliate of nor connected with the Issuer.

Rialto Markets LLC is NOT placing or selling these securities on behalf of the Issuer.

Rialto Markets LLC is NOT soliciting this investment nor making any recommendations by collecting, reviewing, and processing your application for investment.

Rialto Markets LLC conducts Anti-Money Laundering, Identity, and Bad Actor Disqualification reviews of the Issuer, and ensures they are a registered business in good standing.

Rialto Markets LLC is NOT validating or approving the information provided by the Issuer or the Issuer itself.

Contact information below is provided for applicants to make inquiries and requests of Rialto Markets LLC regarding the general application process, the status of the application, or general Reg A regulation-related information. Rialto Markets LLC may direct applicants to specific sections of the Offering Statement to locate information or answers to their inquiry but does not opine or provide guidance on Issuer-related matters.

The offering will be made only by means of an offering circular. An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that the company may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. The securities offered by the company are highly speculative. Investing in shares of common stock of the company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. You may obtain a copy of the Form 1-A offering circular that is part of said offering statement here. You should read the offering circular before making any investment. The offering materials and this letter may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements, which constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

This investment involves a high degree of risk. This investment is suitable only for persons who can bear the economic risk for an indefinite period of time and who can afford to lose their entire investment. Furthermore, investors must understand that such investment is illiquid and is expected to continue to be illiquid for an indefinite period of time. No public market exists for the securities.

This information is presented only for the purpose of providing a general overview of clinical trials. These uses have not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory authorities.